Abstract:
Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
Abstract:
Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
Abstract:
Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.
Abstract:
A closure is removably attachable to a container and comprises a dispensing orifice and a valve element that is biased closed over the orifice. By inverting the container so that a liquid contents of the container exerts pressure on the valve element, or by squeezing the container causing the liquid contents to exert pressure on the valve element, the valve element opens the dispensing orifice allowing the liquid contents to be dispensed from the container. On removing the pressure from the valve element, the valve element resiliently closes the dispensing orifice.
Abstract:
A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.
Abstract:
A venting system of a manually operated trigger sprayer vents the interior of a liquid container connected to the trigger sprayer. The trigger sprayer is provided with a vent chamber that surrounds the pump chamber, and a vent piston that surrounds the pump piston. The vent piston is received in the vent chamber for reciprocating movements between a vent closed and vent opened position in the vent chamber, and the vent chamber having two different interior diameter sections with a larger interior diameter section reducing drag on the vent piston when the vent piston is moved to the vent opened position.
Abstract:
A manually operated liquid foaming dispenser is attached to the top of a container of liquid and is manually reciprocated to dispense the liquid from the container as a foam. The dispenser includes a liquid pump chamber and an air pump chamber that respectively pump liquid and air under pressure to a discharge passage of the pump where the liquid and air are mixed, generating the foam dispensed from the dispenser. The air pump chamber has a tube valve controlling the discharge of air from the air pump to the discharge passage, and the air pump chamber is charged with air by opening the air pump chamber to the exterior environment of the dispenser.
Abstract:
The present invention provides isolated DNA molecules comprising a DNA segment encoding novel human Kunitz-type inhibitors. Also provided are DNA constructs comprising a first DNA segment encoding a novel human Kunitz-type inhibitor wherein said first DNA segment is operably linked to additional DNA segments required for the expression for the first DNA segment, as well as host cells containing such DNA constructs and methods for producing proteins from the host cells.